[The possible value of diagnosing MCI-DLB and treatment options].
Dementia with Lewy Bodies (DLB) is a well-described clinical entity. DLB patients can be treated with acetylcholinesterase inhibitors (AChEI's). However, should we also treat patients who have but part of the symptoms and who are currently described as MCI-DLB? Will these MCI-DLB patients benefit from AChEI's in terms of direct effect on cognition and behaviour and final outcome? Two cases are presented to demonstrate the clinical features of MCI-DLB and the effect of treatment with rivastigmine (AChEI). The discussion then focuses on the possible value of diagnosing MCI-DLB and if this diagnosis should result in a different medication treatment than the diagnosis MCI-AD, for which AChEI medication is not recommended.
Feitsma
M T
MT
Klinisch Geriater, Amphia Ziekenhuis, Breda. Tfeitsma@amphia.nl
van Laar
T
T
Dautzenberg
P L J
PL
D000369:Aged, 80 and over; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000188:drug therapy*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D011379:Prognosis; D000068836:Rivastigmine; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine